{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T08:40:12Z","timestamp":1683189612712},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,8,24]],"date-time":"2005-08-24T00:00:00Z","timestamp":1124841600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>To compare the adverse events after initiation of nevirapine-based ART among HIV-infected patients who did not receive fluconazole (group A), received fluconazole 400 mg\/week (group B), and received fluconazole 200 mg\/day (group C).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective cohort study was conducted among HIV-infected patients who began NVP-based ART between December 2003 and September 2004. Patients were followed up for 6 months. Clinical hepatitis, elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (&gt; 3 times from baseline), and skin rashes were studied.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 686 patients; 225, 392, and 69 patients in group A, B, and C, respectively. Baseline characteristics including age, previous opportunistic infections, use of antituberculous drugs, and baseline aminotransferase levels among the three groups were similar. Group C had a higher proportion of men (<jats:italic>p<\/jats:italic>= 0.016). Baseline median (IQR) CD4 cell counts were 85 (21\u2013159), 18 (7\u201348), and 16 (5\u201335) cell\/mm<jats:sup>3<\/jats:sup>in group A, B, and C, respectively (<jats:italic>p<\/jats:italic>&lt; 0.001). Of 2\/225 (0.9%), 4\/392 (1.0%), and 0\/69 (0%) patients in group A, B, and C developed clinical hepatitis (<jats:italic>p<\/jats:italic>= 0.705). There were no significant difference of elevated AST or ALT among the three groups (<jats:italic>p<\/jats:italic>&gt; 0.05). By logistic regression, receiving fluconazole was not predictive of clinical hepatitis, elevated aminotransferase, or skin rashes. At 6 months after initiating NVP, 174 (77.3%) patients in group A, 309 (78.8%) patients in group B, and 58 (84.1%) patients in group C remained on NVP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Initiation of NVP-based ART among Thais with advance HIV disease receiving fluconazole is safe and well-tolerated. nevirapine should not be contraindicated for patients receiving fluconazole for treatment or prophylaxis of cryptococcosis.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1471-2334-5-67","type":"journal-article","created":{"date-parts":[[2005,8,24]],"date-time":"2005-08-24T18:13:57Z","timestamp":1124907237000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study"],"prefix":"10.1186","volume":"5","author":[{"given":"Weerawat","family":"Manosuthi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nopphanath","family":"Chumpathat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achara","family":"Chaovavanich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somnuek","family":"Sungkanuparph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,8,24]]},"reference":[{"key":"215_CR1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1001\/jama.279.6.450","volume":"279","author":"RS Hogg","year":"1998","unstructured":"Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, Montaner JS: Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. Jama. 1998, 279: 450-454. 10.1001\/jama.279.6.450.","journal-title":"Jama"},{"key":"215_CR2","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1056\/NEJM199803263381301","volume":"338","author":"FJJ Palella","year":"1998","unstructured":"Palella FJJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998, 338: 853-860. 10.1056\/NEJM199803263381301.","journal-title":"N Engl J Med"},{"key":"215_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2174\/1570162043351057","volume":"2","author":"D Dionisio","year":"2004","unstructured":"Dionisio D, Esperti F, Messeri D, Vivarelli A: Priority strategies for sustainable fight against HIV\/AIDS in low-income countries. Curr HIV Res. 2004, 2: 377-393. 10.2174\/1570162043351057.","journal-title":"Curr HIV Res"},{"key":"215_CR4","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1086\/375367","volume":"37","author":"SH Vermund","year":"2003","unstructured":"Vermund SH, Powderly WG: Developing a human immunodeficiency virus\/acquired immunodeficiency syndrome therapeutic research agenda for resource-limited countries: a consensus statement. Clin Infect Dis. 2003, 37: S4-12. 10.1086\/375367.","journal-title":"Clin Infect Dis"},{"key":"215_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/00042560-199901010-00002","volume":"20","author":"M Floridia","year":"1999","unstructured":"Floridia M, Bucciardini R, Ricciardulli D, Fragola V, Pirillo MF, Weimer LE, Tomino C, Giannini G, Galluzzo CM, Andreotti M, Cargnel A, Alberici F, De Rienzo B, Leoncini F, Fiaccadori F, Francisci D, Grillone W, Ortona L, Piazza M, Scalzini A, Nigra E, Tumietto F, Vella S: A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1999, 20: 11-19.","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"215_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1468-1293.2004.00195.x","volume":"5","author":"W Manosuthi","year":"2004","unstructured":"Manosuthi W, Sungkanuparph S, Vibhagool A, Rattanasiri S, Thakkinstian A: Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naive patients with advanced HIV infection. HIV Med. 2004, 5: 105-109. 10.1111\/j.1468-1293.2004.00195.x.","journal-title":"HIV Med"},{"key":"215_CR7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/135965350200700202","volume":"7","author":"D Podzamczer","year":"2002","unstructured":"Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, Luna E, Gonzalez A, Pedrol E, Lozano L, Ocana I, Llibre JM, Casiro A, Aranda M, Barrufet P, Martinez-Lacasa J, Miro JM, Badia X, Casado A, Lupo S, Cahn P, Manos M, Estela J: A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine\/lamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther. 2002, 7: 81-90.","journal-title":"Antivir Ther"},{"key":"215_CR8","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","volume":"363","author":"F van Leth","year":"2004","unstructured":"van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW, Lange JM: Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004, 363: 1253-1263. 10.1016\/S0140-6736(04)15997-7.","journal-title":"Lancet"},{"key":"215_CR9","unstructured":"Scaling up Antiretroviral Therapy in Resource-limited Settings: Treatment Guidelines for a public Health Approach. 2003, Geneva, Joint United Nations Programme on HIV\/AIDS (UNAIDS) and World Health Organization (WHO)"},{"key":"215_CR10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1586\/14787210.2.3.367","volume":"2","author":"A Milinkovic","year":"2004","unstructured":"Milinkovic A, Martinez E: Nevirapine in the treatment of HIV. Expert Rev Anti Infect Ther. 2004, 2: 367-373. 10.1586\/14787210.2.3.367.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"215_CR11","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/S0149-2918(98)80105-7","volume":"20","author":"RB Pollard","year":"1998","unstructured":"Pollard RB, Robinson P, Dransfield K: Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther. 1998, 20: 1071-1092. 10.1016\/S0149-2918(98)80105-7.","journal-title":"Clin Ther"},{"key":"215_CR12","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0029-7844(02)02620-0","volume":"101","author":"E Knudtson","year":"2003","unstructured":"Knudtson E, Para M, Boswell H, Fan-Havard P: Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. Obstet Gynecol. 2003, 101: 1094-1097. 10.1016\/S0029-7844(02)02620-0.","journal-title":"Obstet Gynecol"},{"key":"215_CR13","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1097\/00126334-200309011-00005","volume":"34 Suppl 1","author":"JO Stern","year":"2003","unstructured":"Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL: A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr. 2003, 34 Suppl 1: S21-33.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"215_CR14","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1086\/313757","volume":"30","author":"MS Saag","year":"2000","unstructured":"Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, Sobel JD, Dismukes WE: Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis. 2000, 30: 710-718. 10.1086\/313757.","journal-title":"Clin Infect Dis"},{"key":"215_CR15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1468-1293.2004.00201.x","volume":"5","author":"P Chetchotisakd","year":"2004","unstructured":"Chetchotisakd P, Sungkanuparph S, Thinkhamrop B, Mootsikapun P, Boonyaprawit P: A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency. HIV Med. 2004, 5: 140-143. 10.1111\/j.1468-1293.2004.00201.x.","journal-title":"HIV Med"},{"key":"215_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2165\/00002018-199818020-00001","volume":"18","author":"E Albengres","year":"1998","unstructured":"Albengres E, Le Louet H, Tillement JP: Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf. 1998, 18: 83-97.","journal-title":"Drug Saf"},{"key":"215_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2165\/00003088-200039030-00003","volume":"39","author":"JI Kuper","year":"2000","unstructured":"Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000, 39: 203-214.","journal-title":"Clin Pharmacokinet"},{"key":"215_CR18","first-page":"260","volume":"151","author":"V Joly","year":"2000","unstructured":"Joly V, Yeni P: [Non-nucleoside reverse transcriptase inhibitors]. Ann Med Interne (Paris). 2000, 151: 260-267.","journal-title":"Ann Med Interne (Paris)"},{"key":"215_CR19","first-page":"369","volume-title":"The effect of fluconazole on nevirapine pharmacokinetics: July 11-16; Bangkok.","author":"J Geel","year":"2004","unstructured":"Geel J, Pitt J, Orrell CJ, Van Dyk M, Wood R: The effect of fluconazole on nevirapine pharmacokinetics: July 11-16; Bangkok. 2004, , 1: 369-"},{"key":"215_CR20","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1086\/428093","volume":"191","author":"I Sanne","year":"2005","unstructured":"Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, Wakeford C, Shaw A, Quinn J, Gish RG, Rousseau F: Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005, 191: 825-829. 10.1086\/428093.","journal-title":"J Infect Dis"},{"key":"215_CR21","first-page":"118","volume":"16","author":"K Reisler","year":"2001","unstructured":"Reisler K: High hepatotoxicity rate seen among HAART patients. AIDS Alert. 2001, 16: 118-119.","journal-title":"AIDS Alert"},{"key":"215_CR22","first-page":"1185","volume":"96","author":"S Stranges","year":"2004","unstructured":"Stranges S, Freudenheim JL, Muti P, Farinaro E, Russell M, Nochajski TH, Trevisan M: Greater hepatic vulnerability after alcohol intake in African Americans compared with Caucasians: a population-based study. J Natl Med Assoc. 2004, 96: 1185-1192.","journal-title":"J Natl Med Assoc"},{"key":"215_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0167-8140(02)00003-8","volume":"62","author":"B Ma","year":"2002","unstructured":"Ma B, Yeo W, Hui P, Ho WM, Johnson PJ: Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer -- a retrospective review of Chinese patients and comparison with an historic Western series. Radiother Oncol. 2002, 62: 185-189. 10.1016\/S0167-8140(02)00003-8.","journal-title":"Radiother Oncol"},{"key":"215_CR24","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/j.1365-2125.1986.tb02953.x","volume":"22","author":"JA Critchley","year":"1986","unstructured":"Critchley JA, Nimmo GR, Gregson CA, Woolhouse NM, Prescott LF: Inter-subject and ethnic differences in paracetamol metabolism. Br J Clin Pharmacol. 1986, 22: 649-657.","journal-title":"Br J Clin Pharmacol"},{"key":"215_CR25","first-page":"760","volume":"87","author":"T Anekthananon","year":"2004","unstructured":"Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, Suwanagool S: Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study. J Med Assoc Thai. 2004, 87: 760-767.","journal-title":"J Med Assoc Thai"},{"key":"215_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/00126334-200305010-00007","volume":"33","author":"JS Montaner","year":"2003","unstructured":"Montaner JS, Cahn P, Zala C, Casssetti LI, Losso M, Hall DB, Wruck J, McDonough M, Gigliotti M, Robinson PA: Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. J Acquir Immune Defic Syndr. 2003, 33: 41-46.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"215_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/00042560-200109010-00003","volume":"28","author":"H Knobel","year":"2001","unstructured":"Knobel H, Miro JM, Domingo P, Rivero A, Marquez M, Force L, Gonzalez A, De Miguel V, Sanz J, Boix V, Blanco JL, Locutura J: Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: the GESIDA 09\/99 study. J Acquir Immune Defic Syndr. 2001, 28: 14-18.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"215_CR28","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00228-004-0769-5","volume":"60","author":"E Dailly","year":"2004","unstructured":"Dailly E, Billaud E, Reliquet V, Breurec S, Perre P, Leautez S, Jolliet P, Bourin M, Raffi F: No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors. Eur J Clin Pharmacol. 2004, 60: 343-348. 10.1007\/s00228-004-0769-5.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-5-67.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-5-67\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-5-67","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-5-67.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T08:26:31Z","timestamp":1683188791000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-5-67"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,24]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["215"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-5-67","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,24]]},"assertion":[{"value":"29 May 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"67"}}